Focusing on GPC1, continuous CoxPH analysis, which allows description of survival time as a function of prognostic factor and diagnostic tool, revealed statistically significant and negative correlation between GPC1 expression levels and patients’ survival in 10 particular cancer types i.e., aggressive carcinomas in bladder, colon, kidney, liver, lung, ovary and uterus (BLCA, COAD, KIRC, LIHC, LUAC, OV and UCS) as well as in glioma (LGG), mesothelioma (MESO) and uveal melanoma (UVM). This evidence concerns the gene GPC1 and glioma.